The irreversible inhibitor of monoamine oxidase phenelzine has been studied in the treatment of social anxiety by at least 3 groups2-4 in over 200 subjects, and in all of these clinical trials it produced a positive response with a rate of 63% to 75%, compared with a placebo response rate of about 20% or less.